Lexicon Advances LX1031 For Irritable Bowel Syndrome Into Phase 1b Clinical Trial

Following positive results from a Phase 1a study, Lexicon Genetics Incorporated (Nasdaq: LEXG) has initiated a Phase 1b clinical trial of its investigational new drug LX1031 for irritable bowel syndrome. LX1031 was found to be well-tolerated at all doses tested in the recently completed Phase 1a randomized, double-blind, ascending single-dose clinical trial. [click link for full article]

Read More: continued here

Filed under: GastroIntestinal / Gastroentorology on May 7th, 2007